Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

First commercially available full length human MTOR protein with superior biological activity released

First commercially available full length human MTOR protein with superior biological activity released

Seattle Genetics to sell common stock in underwritten public offering

Seattle Genetics to sell common stock in underwritten public offering

Silicon dioxide coated rust nanoparticles to fight cervical cancer

Silicon dioxide coated rust nanoparticles to fight cervical cancer

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

FDA accepts Pain Therapeutics NDA resubmission for REMOXY

FDA accepts Pain Therapeutics NDA resubmission for REMOXY

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

World's largest sterile compounding center for oncology patients

World's largest sterile compounding center for oncology patients

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

CRI, Oncovir sign new investment agreement to produce immunological stimulant

CRI, Oncovir sign new investment agreement to produce immunological stimulant

CVAF completes new investment agreement with Oncovir for production of Hiltonol

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

MedImmune announces MEDI-573 preclinical results against many solid tumors

MedImmune announces MEDI-573 preclinical results against many solid tumors

OriGene releases 1,500 mouse monoclonal antibodies

OriGene releases 1,500 mouse monoclonal antibodies

Positive results from nimotuzumab Phase II study for gastric cancer

Positive results from nimotuzumab Phase II study for gastric cancer

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.